Denosumab has become one of the most widely supplied biologics in India for bone health management, spanning two very different clinical worlds — osteoporosis prevention and cancer-related bone protection. For hospitals, pharmacies, and procurement teams, the practical challenge is rarely about treatment decisions, which always rest with the prescribing physician — it is about sourcing the right product, in the right strength, with verified authenticity and proper cold chain handling. This guide looks at denosumab from that distributor’s perspective, helping procurement teams understand what they are ordering and why getting the product selection right matters.
What Is Denosumab?
Denosumab is a fully human monoclonal antibody that targets RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand), a protein involved in the activity of osteoclasts, the cells responsible for breaking down bone tissue. According to approved prescribing information, denosumab is supplied under three brand names in India, each formulated for a distinct clinical purpose. Understanding these differences is essential at the point of procurement, since ordering the wrong product for a department can create real supply chain and patient safety complications further down the line. As always, the choice of product and treatment plan remains a decision for the treating physician — this guide is intended to help distributors and procurement teams understand what they are sourcing, not to substitute for that clinical judgement.
Prolia, Xgeva, and Denorange — Why the Distinction Matters for Procurement
This is the single most important distinction for anyone involved in ordering or dispensing denosumab products in India.
| Prolia | Xgeva | Denorange | |
|---|---|---|---|
| Strength | 60mg/mL | 120mg/1.7mL | 60mg/mL |
| Typical setting | Osteoporosis clinics, endocrinology | Oncology centres, cancer hospitals | Osteoporosis clinics, general hospitals |
| Manufacturer | Amgen (originator) | Amgen (originator) | Indian manufacturer |
| Cold chain requirement | Yes | Yes | Yes |
Although Prolia, Xgeva, and Denorange 60 mg all contain the same denosumab antibody, they are formulated, packaged, and indicated differently according to their respective approved labels. Procurement teams supplying oncology departments should not assume Prolia stock can substitute for Xgeva orders, or vice versa — these products are not interchangeable, and the prescribing physician will have specified one or the other for clinical reasons set out in the approved prescribing information.
Where Denorange Fits in the Indian Market
Denorange is the Indian-manufactured 60mg formulation, positioned as a more accessible-cost alternative to the originator Prolia for hospitals and pharmacies managing osteoporosis caseloads. For distributors, this means Denorange typically moves through a different ordering channel than Xgeva, and hospitals managing both oncology and general osteoporosis patients often need to stock both Denorange and Xgeva side by side, despite the shared active ingredient.
Clinical Areas Where Denosumab Products Are Used
According to manufacturer prescribing information and published clinical literature, denosumab products are used across the following broad areas. This summary is provided for procurement and sourcing context only — treatment decisions for individual patients rest entirely with the prescribing physician and should always follow the current approved label.
1. Postmenopausal Osteoporosis
Prolia and Denorange are indicated, per their approved labels, for postmenopausal women at increased risk of fracture. This is one of the largest volume categories for hospitals and pharmacies stocking denosumab products in India.
2. Bone Loss Associated With Cancer Hormone Therapy
Patients receiving androgen deprivation therapy for prostate cancer, or aromatase inhibitor therapy for breast cancer, are at increased risk of treatment-related bone loss. Prolia and Denorange are approved for this indication per their respective labels.
3. Skeletal-Related Events in Bone Metastases
Xgeva is approved, per its label, for delaying skeletal-related events in patients with bone metastases from solid tumours. This is exclusively an oncology-setting product and is supplied at a different strength and dosing interval than Prolia or Denorange.
4. Giant Cell Tumour of Bone
Xgeva also carries an approved indication for giant cell tumour of bone in adults and skeletally mature adolescents where surgery is not a viable option.
For full and current indication details, procurement teams and prescribers should always refer to the official prescribing information published by the manufacturer or the FDA label for Denosumab and equivalent Indian regulatory documentation.
How Denosumab Products Differ at the Point of Ordering
| Product | Pack Configuration | Typical Department Ordering | Storage Requirement |
|---|---|---|---|
| Prolia 60mg | Pre-filled syringe | Endocrinology, orthopaedics | 2°C–8°C, do not freeze |
| Xgeva 120mg | Vial | Oncology, haematology | 2°C–8°C, do not freeze |
| Denorange 60mg | Vial | Endocrinology, general medicine | 2°C–8°C, do not freeze |
All three products require unbroken cold chain handling from manufacturer through to point of administration. This is one of the most operationally important aspects of sourcing denosumab products — any break in cold chain integrity can compromise the biologic, regardless of which brand is involved.
What Hospitals and Pharmacies Should Verify When Sourcing Denosumab Products
Given the strength-specific differences between Prolia, Xgeva, and Denorange, procurement teams should check the following before accepting delivery:
- Correct strength and brand match against the order — confirming 60mg vs 120mg products are not mixed up at receiving
- Batch number and expiry date clearly visible and matching accompanying documentation
- Cold chain compliance certificates for the shipment, including temperature logs where available
- Manufacturer packaging authenticity — checking for tamper-evident seals and consistent packaging design
- Complete invoice and supply documentation, particularly for institutional bulk orders
Why Sourcing Channel Matters for Biologics Like Denosumab
Biologic medicines such as denosumab carry a higher sourcing risk profile than many conventional pharmaceuticals, given the cold chain dependency and the clinical seriousness of the conditions they treat. Working with a distributor that maintains certified cold chain infrastructure throughout storage and last-mile delivery reduces the risk of product degradation before it reaches the patient. This matters equally whether the product in question is the originator Prolia or Xgeva, or the Indian-manufactured Denorange — cold chain integrity is non-negotiable across all three.
How A.K. Pharma Supplies Denosumab Products
A.K. Pharma is a licensed specialty medicine distributor in Delhi supplying genuine Prolia (Denosumab 60mg), Xgeva (Denosumab 120mg), and Denorange 60 mg to hospitals, oncology centres, endocrinology clinics, and pharmacies across India. As a distributor focused specifically on specialty and imported medicines, A.K. Pharma maintains certified cold chain infrastructure from procurement through last-mile hospital delivery, along with complete batch documentation for every shipment — helping procurement teams source the correct denosumab product with confidence.
Frequently Asked Questions
Can Prolia and Xgeva be substituted for each other when sourcing for a hospital?
No. Although they share the same active ingredient, they are different products with different approved indications, strengths, and dosing intervals per their respective prescribing information. Substitution decisions are not a sourcing matter and should never be made outside of the treating physician’s instructions.
Why does Denorange cost less than Prolia if it contains the same molecule?
Denorange is manufactured in India, which generally allows for more accessible pricing compared to the originator biologic, while following the same approved 60mg strength and formulation standard.
What should a pharmacy check when receiving a denosumab shipment?
Batch number, expiry date, cold chain compliance documentation, and confirmation that the correct brand and strength matches what was ordered, since Prolia, Xgeva, and Denorange are not interchangeable.
Does A.K. Pharma supply all three denosumab products?
Yes. A.K. Pharma supplies Prolia, Xgeva, and Denorange, allowing hospitals and clinics managing both oncology and general osteoporosis caseloads to source all three from a single, cold chain-compliant distributor.
Who should hospitals contact to order denosumab products?
Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current availability and pricing across Prolia, Xgeva, and Denorange.
Disclaimer: This article is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. All treatment decisions, including drug selection and dosing, should be made by a qualified healthcare professional in accordance with the approved prescribing information. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.